Concurrently, CRISPR-mediated epigenetic editing and metabolic intervention technologies offer molecular scalpels for immune reprogramming, nanocarriers enable spatiotemporally precise drug delivery, and AI-driven models accelerate the design of biased ligands and personalized treatment regimens [431]
Here is the part many people miss: your body already makes GLP-1 naturally
Once a single peptide backbone had been shown to be capable of carrying agonist activity at two structurally related class B G-protein-coupled receptors, the obvious next question was whether a third could be added to the same scaffold without losing potency at the first two, and whether the resulting pharmacology behaved like the sum of its parts or like something else
The rationale is straightforward
Sancho-Vaello E, Gil-Carton D, Francois P, Bonetti EJ, Kreir M, Pothula KR